1. Articles from Atox Bio

    1-1 of 1
    1. Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of

      Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of

      "We appreciate and continue to benefit from BARDA's ongoing support in the development of Reltecimod as a novel, host-based, immunomodulatory therapy to treat severe infections," said Dan Teleman, Chief Executive Officer of Atox Bio. "We have a very collaborative partnership with BARDA and look forward to continuing to work together." Reltecimod (AB103) is a rationally designed peptide that binds to the CD28 co-stimulatory receptor to modulate the host's immune response to severe infections. By limiting, but not inhibiting, the body's acute inflammatory response, Reltecimod helps control the cytokine storm that could quickly lead to morbidity and mortality ...

      Read Full Article
      Mentions: Yissum
    1-1 of 1
  1. Categories

    1. News:

      News, Placeholder
  2. Topics in the News

    1. (1 articles) Yissum
  3. Popular Articles

  4. Picture Gallery

    Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Ancient foodies: Study reveals dietary preferences of Jordan Valley early humans Charity, not crime, rises when natural disaster strikes - ISRAEL21c Prof. Eli Keshet to be awarded Israel Prize in life sciences Biopsies can be replaced with simple blood tests, Hebrew U. research find Prof. Yair Zakovitch to receive Israel Prize in Bible Studies One of the oldest mosques in the world uncovered in Tiberias 2020 started with murder hornets, ends with new species of wild bee Stormy weather ahead: pollution found to cause fierce gales in coastal cities Ancient oil lamp workshop, now at Israel Museum, shows the way we once lit Israeli researchers discover how to lengthen life of solar panels One llama’s antibodies, analyzed in Jerusalem, may help ‘millions’ through COVID